The immuno-oncology drug developer has filed for an $86.5m offering, having raised more than $115m in equity funding from investors including Taiho and Eli Lilly.

US-based immunotherapy developer Harpoon Therapeutics has filed to raise up to $86.3m in an initial public offering that would enable pharmaceutical companies Eli Lilly and Taiho to exit. Harpoon is working on T cell engagers intended to treat diseases such as cancer by leveraging the body’s immune system, and aims to have advanced four drug…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.